
Fluid Biopsy Market Size, Share, and Outlook, H2-2025 Report- By Indication (Lung Cancer, Breast Cancer, Colorectal, Others), By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA) and Companies, 2021-2032
Description
Fluid Biopsy Market Outlook
The global Fluid Biopsy Market Size is valued at $12.3 Billion in 2025 and is forecast to reach $25.9 Billion in 2032 at a CAGR of 11.2%.
The Fluid Biopsy Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Fluid Biopsy Market segments across 22 countries from 2021 to 2032. Key segments covered include By Indication (Lung Cancer, Breast Cancer, Colorectal, Others), By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Fluid Biopsy Market Insights, 2025
The fluid biopsy market in 2025 is advancing with innovations in circulating tumor DNA (ctDNA), exosomes, and circulating tumor cell (CTC) detection for early cancer diagnosis and treatment monitoring. Recent product launches focus on high-sensitivity, multiplex platforms capable of detecting low-abundance biomarkers with rapid turnaround times. Companies are integrating AI and bioinformatics solutions to interpret complex molecular profiles and guide personalized therapies. Research emphasizes non-invasive disease monitoring, minimal sample volumes, and enhanced analytical reproducibility. Regulatory oversight ensures clinical validation, diagnostic accuracy, and quality control. Emerging trends include multi-omic analysis, longitudinal monitoring for therapy response, and integration with electronic medical records. Collaborative efforts with oncology centers and clinical trial networks are validating clinical utility. Improvements in automation and sample processing are reducing operator dependency and increasing lab throughput.
Five Trends Shaping the Global Fluid Biopsy Market in 2025 and Beyond
The global Fluid Biopsy Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Fluid Biopsy Industry?
The Fluid Biopsy Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Fluid Biopsy Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Fluid Biopsy Market Segment Insights
The Fluid Biopsy Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Indication (Lung Cancer, Breast Cancer, Colorectal, Others), By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Fluid Biopsy Industry Value Chain
The chapter identifies potential companies and their operations across the global Fluid Biopsy Industry ecosystem. It assists decision-makers in evaluating global Fluid Biopsy Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Fluid Biopsy Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Fluid Biopsy Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Fluid Biopsy Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Fluid Biopsy Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Fluid Biopsy Market.
Europe Fluid Biopsy Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Fluid Biopsy Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Fluid Biopsy Industry competitiveness. The report analyses the key Fluid Biopsy Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Fluid Biopsy Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Fluid Biopsy Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Fluid Biopsy Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Fluid Biopsy Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Fluid Biopsy Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Fluid Biopsy Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Bio-Rad Laboratories Inc, Diagnologix LLC, Exosome Sciences Inc, GRAIL Inc, Guardant Health Inc, Horizon Discovery Group plc, Illumina Inc, Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc, Predicine Inc, QIAGEN N.V.. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Fluid Biopsy Market Scope
Leading Segments
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Leading Companies
Bio-Rad Laboratories Inc
Diagnologix LLC
Exosome Sciences Inc
GRAIL Inc
Guardant Health Inc
Horizon Discovery Group plc
Illumina Inc
Inivata Ltd
Lucence Diagnostics Pte Ltd
LungLife AI Inc
Predicine Inc
QIAGEN N.V.
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Fluid Biopsy Market Size is valued at $12.3 Billion in 2025 and is forecast to reach $25.9 Billion in 2032 at a CAGR of 11.2%.
The Fluid Biopsy Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Fluid Biopsy Market segments across 22 countries from 2021 to 2032. Key segments covered include By Indication (Lung Cancer, Breast Cancer, Colorectal, Others), By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Fluid Biopsy Market Insights, 2025
The fluid biopsy market in 2025 is advancing with innovations in circulating tumor DNA (ctDNA), exosomes, and circulating tumor cell (CTC) detection for early cancer diagnosis and treatment monitoring. Recent product launches focus on high-sensitivity, multiplex platforms capable of detecting low-abundance biomarkers with rapid turnaround times. Companies are integrating AI and bioinformatics solutions to interpret complex molecular profiles and guide personalized therapies. Research emphasizes non-invasive disease monitoring, minimal sample volumes, and enhanced analytical reproducibility. Regulatory oversight ensures clinical validation, diagnostic accuracy, and quality control. Emerging trends include multi-omic analysis, longitudinal monitoring for therapy response, and integration with electronic medical records. Collaborative efforts with oncology centers and clinical trial networks are validating clinical utility. Improvements in automation and sample processing are reducing operator dependency and increasing lab throughput.
Five Trends Shaping the Global Fluid Biopsy Market in 2025 and Beyond
The global Fluid Biopsy Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Fluid Biopsy Industry?
The Fluid Biopsy Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Fluid Biopsy Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Fluid Biopsy Market Segment Insights
The Fluid Biopsy Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Indication (Lung Cancer, Breast Cancer, Colorectal, Others), By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Fluid Biopsy Industry Value Chain
The chapter identifies potential companies and their operations across the global Fluid Biopsy Industry ecosystem. It assists decision-makers in evaluating global Fluid Biopsy Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Fluid Biopsy Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Fluid Biopsy Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Fluid Biopsy Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Fluid Biopsy Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Fluid Biopsy Market.
Europe Fluid Biopsy Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Fluid Biopsy Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Fluid Biopsy Industry competitiveness. The report analyses the key Fluid Biopsy Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Fluid Biopsy Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Fluid Biopsy Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Fluid Biopsy Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Fluid Biopsy Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Fluid Biopsy Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Fluid Biopsy Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Bio-Rad Laboratories Inc, Diagnologix LLC, Exosome Sciences Inc, GRAIL Inc, Guardant Health Inc, Horizon Discovery Group plc, Illumina Inc, Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc, Predicine Inc, QIAGEN N.V.. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Fluid Biopsy Market Scope
Leading Segments
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Leading Companies
Bio-Rad Laboratories Inc
Diagnologix LLC
Exosome Sciences Inc
GRAIL Inc
Guardant Health Inc
Horizon Discovery Group plc
Illumina Inc
Inivata Ltd
Lucence Diagnostics Pte Ltd
LungLife AI Inc
Predicine Inc
QIAGEN N.V.
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
194 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Fluid Biopsy Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Fluid Biopsy Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Fluid Biopsy Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Fluid Biopsy Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Fluid Biopsy Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Indication
- Lung Cancer
- Breast Cancer
- Colorectal
- Others
- By Type
- Circulating Tumor Cells
- Circulating Tumor DNA
- Cell-free DNA
- 6. Global Fluid Biopsy Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Fluid Biopsy Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Fluid Biopsy Market Trends and Growth Opportunities
- 6.2.1 North America Fluid Biopsy Market Outlook by Type
- 6.2.2 North America Fluid Biopsy Market Outlook by Application
- 6.3 North America Fluid Biopsy Market Outlook by Country
- 6.3.1 The US Fluid Biopsy Market Outlook, 2021- 2032
- 6.3.2 Canada Fluid Biopsy Market Outlook, 2021- 2032
- 6.3.3 Mexico Fluid Biopsy Market Outlook, 2021- 2032
- 7. Europe Fluid Biopsy Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Fluid Biopsy Market Trends and Growth Opportunities
- 7.2.1 Europe Fluid Biopsy Market Outlook by Type
- 7.2.2 Europe Fluid Biopsy Market Outlook by Application
- 7.3 Europe Fluid Biopsy Market Outlook by Country
- 7.3.2 Germany Fluid Biopsy Market Outlook, 2021- 2032
- 7.3.3 France Fluid Biopsy Market Outlook, 2021- 2032
- 7.3.4 The UK Fluid Biopsy Market Outlook, 2021- 2032
- 7.3.5 Spain Fluid Biopsy Market Outlook, 2021- 2032
- 7.3.6 Italy Fluid Biopsy Market Outlook, 2021- 2032
- 7.3.7 Russia Fluid Biopsy Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Fluid Biopsy Market Outlook, 2021- 2032
- 8. Asia Pacific Fluid Biopsy Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Fluid Biopsy Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Fluid Biopsy Market Outlook by Type
- 8.2.2 Asia Pacific Fluid Biopsy Market Outlook by Application
- 8.3 Asia Pacific Fluid Biopsy Market Outlook by Country
- 8.3.1 China Fluid Biopsy Market Outlook, 2021- 2032
- 8.3.2 India Fluid Biopsy Market Outlook, 2021- 2032
- 8.3.3 Japan Fluid Biopsy Market Outlook, 2021- 2032
- 8.3.4 South Korea Fluid Biopsy Market Outlook, 2021- 2032
- 8.3.5 Australia Fluid Biopsy Market Outlook, 2021- 2032
- 8.3.6 South East Asia Fluid Biopsy Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Fluid Biopsy Market Outlook, 2021- 2032
- 9. South America Fluid Biopsy Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Fluid Biopsy Market Trends and Growth Opportunities
- 9.2.1 South America Fluid Biopsy Market Outlook by Type
- 9.2.2 South America Fluid Biopsy Market Outlook by Application
- 9.3 South America Fluid Biopsy Market Outlook by Country
- 9.3.1 Brazil Fluid Biopsy Market Outlook, 2021- 2032
- 9.3.2 Argentina Fluid Biopsy Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Fluid Biopsy Market Outlook, 2021- 2032
- 10. Middle East and Africa Fluid Biopsy Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Fluid Biopsy Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Fluid Biopsy Market Outlook by Type
- 10.2.2 Middle East and Africa Fluid Biopsy Market Outlook by Application
- 10.3 Middle East and Africa Fluid Biopsy Market Outlook by Country
- 10.3.1 Saudi Arabia Fluid Biopsy Market Outlook, 2021- 2032
- 10.3.2 The UAE Fluid Biopsy Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Fluid Biopsy Market Outlook, 2021- 2032
- 10.3.4 South Africa Fluid Biopsy Market Outlook, 2021- 2032
- 10.3.5 Egypt Fluid Biopsy Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Fluid Biopsy Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Bio-Rad Laboratories Inc
- Diagnologix LLC
- Exosome Sciences Inc
- GRAIL Inc
- Guardant Health Inc
- Horizon Discovery Group plc
- Illumina Inc
- Inivata Ltd
- Lucence Diagnostics Pte Ltd
- LungLife AI Inc
- Predicine Inc
- QIAGEN N.V.
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.